The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Polysaccharide antigens of the capsule of Cryptococcus neoformans
Open accessAbstract
The major significance of the capsular polysaccharide of C. neoformans is its role in potentiating opportunistic infections by the yeast. It has the ability to exert a broad spectrum of influences on the immune response, from activation of phagocytic cells and complement components of the alternative pathway, to the induction of specific antibody, T-suppressor cells, DTH responses, and cytokines (51). These biological properties along with the serotype specificities are all determined by the physical properties and chemical structures of the polysaccharide antigens that compose the capsule. There is evidence not only for an association of lethal infections with serotype A in patients with advanced AIDS (34, 56), but also for a role for the capsule in directly influencing the infection of CD4+ cells by HIV (57). Together, these phenomena raise intriguing questions about the possible connection between the chemistry of these capsular antigens and cryptococcal infections in AIDS patients. One speculation is that AIDS creates the optimal physiological conditions for the establishment and spread of cryptococcosis. It has been observed that during the progression of AIDS there is a shift towards a T-2 response (14). This could lead to conditions that would inhibit the cellular immune responses that block dissemination of cryptococcal infections. Thus, an important consideration in the application of vaccine or immune modulation therapies in the treatment of cryptococcosis in AIDS victims would be the design of vaccines that could boost the T-1 immune response. It has been shown that the form and dose of an antigenic challenge can influence the induction of a T-1 or T-2 immune response (61). Recently, Murphy has reported that gamma interferon and interleukin 2 are up-regulated in the spleens of mice that produce anticryptococcal TDH and TAMP cells in response to immunogenic doses of cryptococcal culture filtrate antigen given with Freund's complete adjuvant (49). Perhaps purified cryptococcal antigens (e.g., MP) conjugated to an appropriate carrier or adjuvant could be used in therapeutic strategies to limit cryptococcosis in immunocompromised individuals. Future investigations of virulence and pathogenicity in the context of defined polysaccharide antigens from encapsulated strains of C. neoformans will contribute to a better understanding of the regulation of cryptococcal infection and immunity at the cellular and molecular levels.(ABSTRACT TRUNCATED AT 400 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clerici, M., Hakim, F. T., Venzon, D. J., Blatt, S., Hendrix, C. W., Wynn, T. A., & Shearer, G. M. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116294 · Cited by 469
Protective murine monoclonal antibodies to Cryptococcus neoformans
Mukherjee, J., Scharff, M. D., & Casadevall, A. (1992) · Infection and Immunity · doi:10.1128/iai.60.11.4534-4541.1992 · Cited by 282
The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages
Kozel, T. R., & Gotschlich, E. C. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.4.1994 · Cited by 239
Murphy, J. W., & Cozad, G. C. (1972) · Infection and Immunity · doi:10.1128/iai.5.6.896-901.1972 · Cited by 204
Decreased virulence in stable, acapsular mutants ofCryptococcus neoformans
Fromtling, R. A., Shadomy, H. J., & Jacobson, E. S. (1982) · Mycopathologia · doi:10.1007/bf00636177 · Cited by 202
Ikeda, R., Shinoda, T., Fukazawa, Y., & Kaufman, L. (1982) · Journal of Clinical Microbiology · doi:10.1128/jcm.16.1.22-29.1982 · Cited by 200
Capsular Polysaccharides of Cryptococcus neoformans
Bhattacharjee, A. K., Bennett, J. E., & Glaudemans, C. P. J. (1984) · Clinical Infectious Diseases · doi:10.1093/clinids/6.5.619 · Cited by 192
Collins, H. L., & Bancroft, G. J. (1992) · European Journal of Immunology · doi:10.1002/eji.1830220617 · Cited by 176
Cherniak, R., Reiss, E., Slodki, M. E., Plattner, R. D., & Blumer, S. O. (1980) · Molecular Immunology · doi:10.1016/0161-5890(80)90096-6 · Cited by 158
Self-citationA galactoxylomannan antigen of Cryptococcus neoformans serotype A
Cherniak, R., Reiss, E., & Turner, S. H. (1982) · Carbohydrate Research · doi:10.1016/s0008-6215(00)80686-2 · Cited by 152
Self-citation
Cited by
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans
Mitchell, T. G., & Perfect, J. R. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.515 · Cited by 1,213
Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex
Hagen, F., Khayhan, K., Theelen, B., Kolecka, A., Polacheck, I., Sionov, E., Falk, R., Parnmen, S., Lumbsch, H. T., & Boekhout, T. (2015) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2015.02.009 · Cited by 687
What Makes Cryptococcus neoformans a Pathogen?
Buchanan, K. L., & Murphy, J. W. (1998) · Emerging Infectious Diseases · doi:10.3201/eid0401.980109 · Cited by 325
Casadevall, A., Cleare, W., Feldmesser, M., Glatman-Freedman, A., Goldman, D. L., Kozel, T. R., Lendvai, N., Mukherjee, J., Pirofski, L.-A., Rivera, J., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.6.1437 · Cited by 298
Nosanchuk, J. D., & Casadevall, A. (1997) · Infection and Immunity · doi:10.1128/iai.65.5.1836-1841.1997 · Cited by 170
Metadata
- Authors
- Cherniak, R., & Sundstrom, J. B.
- Venue
- Infection and Immunity
- Publisher
- American Society for Microbiology
- Published
- 1994-05
- Volume
- 62
- Issue
- 5
- Pages
- 1507-1512
- ISSN
- 0019-9567 (ISSN-L)
- 1098-5522
- OpenAlex
- W2115161719
- Cited by
- 320
- References
- 66
- FWCI
- 13.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polysaccharide antigens of the capsule of Cryptococcus neoformans. https://app.cochat.ai/papers/10.1128/iai.62.5.1507-1512.1994
- The paper
- Cherniak, R., & Sundstrom, J. B. (1994). Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infection and Immunity. https://doi.org/10.1128/iai.62.5.1507-1512.1994
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.